Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
5.45
+0.07 (1.30%)
At close: Jul 20, 2026, 4:00 PM EDT
5.46
+0.01 (0.20%)
Pre-market: Jul 21, 2026, 5:00 AM EDT
Unicycive Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Unicycive Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $38.59. The average 1-year stock price forecast is 608.07% higher than the current stock price, while the lowest is $13 (+138.53%) and the highest is $90 (+1,551.38%).
Price Target: $38.59 (+608.07%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Unicycive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 8 | 8 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Reiterates $30 | Buy | Reiterates | $30 | +450.46% | Jul 10, 2026 |
| Noble Financial | Noble Financial | Buy Reiterates $60 → $50 | Buy | Reiterates | $60 → $50 | +817.43% | Jul 1, 2026 |
| Benchmark Co. | Benchmark Co. | Buy Maintains $18 → $13 | Buy | Maintains | $18 → $13 | +138.53% | Jul 1, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $37 | Buy | Maintains | $37 | +578.90% | Jul 1, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $15 | Buy | Reiterates | $15 | +175.23% | Jul 1, 2026 |
Financial Forecast
Revenue This Year
3.80M
Revenue Next Year
288.38M
from 3.80M
Increased by 7,480.16%
EPS This Year
-1.42
from -1.67
EPS Next Year
5.15
from -1.42
EPS and Forward PE are based on non-GAAP adjusted numbers.